Xconomy: Join Us at “Biotech in the Belt-Tightening Era” April 9 in Seattle
Summary
For a long time, biotech companies could get away with believing that if they offered patients important new drugs, devices or diagnostics they could essentially impose high prices on U.S. health insurers.So I’m excited to pull together a stellar lineup of speakers to discuss this trend at the next big Xconomy event—“Biotech in the Belt-Tightening Era.” This event will be held the afternoon of April 9 at Northeastern University’s new Seattle office at 401 Terry Avenue North.This company did it by blazing a trail with insurers, persuading them to pay several thousand dollars for a genetic test that can predict whether an individual woman’s breast cancer is likely to recur after surgery, and whether she is likely to benefit from a round of preventive chemotherapy.Stack recently left her job as a go-to life sciences partner at Kleiner Perkins Caufield & Byers to join GE’s $6 billion healthymagination program.Siegall’s company delivered the goods almost two years ago, introducing the first commercially successful “empowered antibody” and the biggest innovation for a couple of rare lymphomas in decades.